Sponsored Links
| Vertex Plans To Provide Access To Potential CF Therapy VX-770 For Patients With Critical Medical Need |
 |
 |
 |
| Pharmacy - Pharma Industry - Biotech Industry | |||
|
Vertex Pharmaceuticals Inc. announced a plan to provide VX-770, a CF medicine in development, to people with the G551D mutation who are in critical medical need and may benefit from treatment prior to potential approval of the drug from the U.S. Food and Drug Administration (FDA)... Read more: Pharma Industry / Biotech Industry News From Medical News Today
|